Latest Top Picks

Stock Opinions by Michelle Calpin

TOP PICK
(Was a top pick on Mar 23 no change) A fan of pharmaceuticals and thinks this is the best. Goor R&D and sales.
TOP PICK
Good assets. 6% dividend. Good valuation. 16 X earnings. Has growth potential.
BUY
Prefers over Ericcson. Dominant in the sector.
DON'T BUY
Prefers Nokia. Questions visibilty and their need to issue more shares.
DON'T BUY
Slow growth. Walmart can be a competitor.
DON'T BUY
Too speculative.
BUY
Good long term. Well established.
DON'T BUY
Very strong with big growth, but 39 P/E is too high. Has a lot of competition, eg Wal Mart, etc.
BUY
Very steady. Has a bumpy road to maintain its strong growth.
DON'T BUY
Very reasonable valuation. Patents are coming off. Prefers Pfizer.
DON'T BUY
Very reasonable valuation. Patents are coming off. Prefers Pfizer.
BUY
In exciting sectors. Good cash. Expects it to turn strongly.
DON'T BUY
Too expensive. 60 X P/E. Up because it has a cult following.
DON'T BUY
Trading at reasonable values, but slow growth and competition.
BUY
Has done well. Good steady growth. A long term hold.
Showing 1 to 15 of 60 entries